Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini
… based on novel RNA editing technologies including our Axiomer ® technology." Dr. Yu is a professor of biochemistry … that do not currently have treatment options." About Axiomer ® Technology Platform ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …
… in patients with LCA10 and preclinical data for ProQR’s Axiomer ® RNA-editing technology. Abstract titles: ○ … through intravitreal injections in the eye. About Axiomer ® Technology Platform ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …
… into other forms of genetic blindness Validate and expand Axiomer ® : Further validate and expand ProQR's proprietary Axiomer ® RNA editing platform through first development … QR-1123, QR-421a, QR-411a, QR-504, the potential of our Axiomer ® editing platform, our plans and timing of …
… into clinical development and further advance our novel Axiomer ® RNA editing platform. With these events we look … or halt corneal degeneration in patients with FECD3. About Axiomer ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …